Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Matthew D Galsky and Dr Ashish M Kamat, including the following topics:
Introduction: Urologist for Life (0:00) Non-Muscle-Invasive Urothelial Bladder Cancer (UBC) Update (9:54) Enfortumab Vedotin/Pembrolizumab Now and in the Future (30:21) HER2-Positive UBC (37:33) Future Directions — ctDNA (55:39) CME information and select publications

Featuring perspectives from Ms Ilene Galinsky, Dr Andrew T Kuykendall, Dr Sara M Tinsley-Vance and Dr Abdulraheem Yacoub, including the following topics:
Introduction (0:00) The Biology of Myelofibrosis (MF) (14:00) Role of Available and Investigational JAK inhibitors for the Management of MF (45:49) Promising Agents and Strategies for Patients with MF (1:23:17) NCPD information and select publications

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics:
Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00) Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01) The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02) Side Effects Associated with PARP Inhibitors (29:58) Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29) The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11) PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36) The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14) Toxicities with Mirvetuximab Soravtansine (1:11:53) The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18) NCPD information and select publications

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics:
Introduction (0:00) The Biology of Head and Neck Cancer (15:41) The Multidisciplinary Treatment of Head and Neck Cancer (18:14) Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03) Radiation Therapy and Chemotherapy Side Effects (41:02) The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50) Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46) Tolerability Considerations with Xevinapant (1:06:13) The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35) Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27) The Tolerability of Immune Checkpoint Inhibitors (1:24:09) NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Adam S Kibel, Dr Laurence Klotz and Dr Sandy Srinivas, moderated by Dr Elisabeth I Heath, including the following topics:
Introduction (0:00) Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel (2:39) Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz (27:04) Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal (51:07) New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas (1:13:53) Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath (1:38:52) CME information and select publications

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics:
Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications